摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(8S,9S,10R,13R,14S,17R)-3-[2-hydroxy-1-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl] carbamate

中文名称
——
中文别名
——
英文名称
[(8S,9S,10R,13R,14S,17R)-3-[2-hydroxy-1-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl] carbamate
英文别名
——
[(8S,9S,10R,13R,14S,17R)-3-[2-hydroxy-1-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl] carbamate化学式
CAS
——
化学式
C36H63NO7
mdl
——
分子量
621.9
InChiKey
YYISWEFXMDVKLG-SNLBPHPQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.6
  • 重原子数:
    44
  • 可旋转键数:
    18
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    121
  • 氢给体数:
    3
  • 氢受体数:
    7

文献信息

  • [EN] BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS<br/>[FR] INHIBITEURS DE KINASE DIFLUORODIOXALANE-AMINOBENZIMIDAZOLE POUR LE TRAITEMENT D'UN CANCER, D'UNE INFLAMMATION AUTO-IMMUNE ET DE TROUBLES DU SNC
    申请人:4SC DISCOVERY GMBH
    公开号:WO2014001464A1
    公开(公告)日:2014-01-03
    The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, (I) wherein A is a bond, alkyl or alkoxy optionally substituted with one or more R" as defined herein, *-N(R"')CO-, *-CON(R"')-, *-N(R'")CON(R"')-, -S-, -SO-, *-N(R'")-, *-N(R'")CO-, *-CON(R'")-, -CO-, *-COO-, *-OOC-, *-S02N(R"')-, -S02, or *-N(R"')-SO2-, wherein R"' is as defined herein and * specifies the point of attachment to X; X is aryl, cycloalkyl, aralkyl, heterocyclyl or heteroaryl, which may be substituted with one or more Rx further described herein; L is a bond or *-N(RN)CO-, *-CON(RN)-, *-N(RN)-, *-C=N(RN)-, *-N(RN)-alkyI-, *-alkyl-N(RN)-, *-N(RN)CON(RN)-, *-CO-, *-S02-, alkyl, *-alkyl-0-alkyl-, *-NCO-CH=CH-, *-CH=CH-CONH-, * -S02N(RN)-, *-N(RN)S02-, or heterocyclyl, wherein * specifies the point of attachment to X; Y is H, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heteroaryl, which may be substituted with one or more RY further described herein; and R and RN are further described herein; as well as their use as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
    该发明涉及一般式(I)的化合物或其生理功能衍生物、溶剂或盐,其中(I)中A是键,烷基或烷氧基,可选择地用一个或多个如下所定义的R"取代,*-N(R"')CO-,*-CON(R"')-,*-N(R'")CON(R"')-,-S-,-SO-,*-N(R'")-,*-N(R'")CO-,*-CON(R'")-,-CO-,*-COO-,*-OOC-,*-S02N(R"')-,-S02,或*-N(R"')-SO2-,其中R"'如此定义,*指定连接到X的点;X是芳香族,环烷基,芳基烷基,杂环烷基或杂芳基,可用一个或多个Rx进一步描述;L是键或*-N(RN)CO-,*-CON(RN)-,*-N(RN)-,*-C=N(RN)-,*-N(RN)-烷基-,*-烷基-N(RN)-,*-N(RN)CON(RN)-,*-CO-,*-S02-,烷基,*-烷基-0-烷基-,*-NCO-CH=CH-,*-CH=CH-CONH-,*-S02N(RN)-,*-N(RN)S02-,或杂环烷基,其中*指定连接到X的点;Y是H,烷基,芳基,芳基烷基,环烷基,杂环烷基或杂芳基,可用一个或多个RY进一步描述;R和RN在此进一步描述;以及它们作为药物的用途,包括它们的药物组合物,治疗或预防涉及其管理的医疗状况的方法,以及在制造用于治疗或预防医疗状况的药物中的用途,特别是自身免疫性炎症性疾病、中枢神经系统疾病、睡眠障碍或包括癌症在内的增殖性疾病。该发明还涉及一种特定的制备上述化合物的过程。
  • BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS
    申请人:4SC DISCOVERY GMBH
    公开号:US20150158878A1
    公开(公告)日:2015-06-11
    The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein A, X, L, Y, R, and R N are as defined herein. The invention further relates to the use of the compounds of formula (I) as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
    本发明涉及一种通式(I)的化合物或其生理功能衍生物、溶剂或盐,其中A、X、L、Y、R和RN如本文所定义。本发明还涉及将通式(I)的化合物用作药物,包括它们的制药组合物,以及治疗或预防需要其给药的医疗状况的方法,以及将其用于制造治疗或预防医疗状况的药物,尤其是自身免疫炎症性疾病、中枢神经系统疾病、睡眠障碍或增殖性疾病,包括癌症。本发明还涉及一种特定的制备上述化合物的方法。
  • US9580438B2
    申请人:——
    公开号:US9580438B2
    公开(公告)日:2017-02-28
  • US9744247B2
    申请人:——
    公开号:US9744247B2
    公开(公告)日:2017-08-29
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B